Dr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Current projects aim to better understand the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses--both as a mechanism of intracellular trafficking and trigger of virus assembly, and as a target for a promising antiviral treatment. The function and cell biology of hepatitis and respiratory virus proteins are also being studied, with a focus on identifying key determinants of pathogenesis and designing novel antiviral strategies for hepatitis, influenza, and enteroviruses. Of particular interest are targets in host cells upon which viruses depend, and critical RNA secondary structures in viruses. Other interests include exploitation of hepatic stem cells, development of small animal models, NASH, liver cancer, and engineered human liver tissues.